文献速递免疫规划妇幼与学校卫生

美国孕产妇接种三组分无细胞百日咳疫苗预防婴儿百日咳的有效性:基于贝叶斯动态借用的病例对照研究事后分析

Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing.
PubMed 文献 · Vaccine · 2023-08-25

该研究对美国六个新兴感染项目网络州2011至2014年病例对照研究进行事后亚组分析,纳入108例病例和183例对照,评估孕晚期接种三组分无细胞百日咳疫苗预防2月龄以下婴儿百日咳的有效性。基于美国数据疫苗有效性为78.0%(95%CI:-38.0;96.5),贝叶斯动态借用非美国数据后为83.4%(95%可信区间:55.7;92.5)。

要点

  • 孕晚期接种Td3ap疫苗预防2月龄以下婴儿百日咳的疫苗有效性基于美国数据为78.0%(95%CI:-38.0;96.5)。
  • 贝叶斯动态借用非美国数据(历史数据权重90%)估计疫苗有效性为83.4%(95%可信区间:55.7;92.5)。
  • 作者结论认为美国孕晚期接种Td3ap疫苗预防婴儿百日咳的有效性很可能≥50%,最可能约为80%。

核心结论

  • 美国孕晚期接种三组分无细胞百日咳疫苗预防婴儿百日咳的有效性很可能≥50%,最可能约为80%。
  • 贝叶斯动态借用非美国疫苗有效性数据克服了品牌特异性亚组分析因样本量小导致的检验效能有限。

研究设计与样本

  • 对2011至2014年美国六个新兴感染项目网络州开展的病例对照研究进行事后亚组分析。
  • 分析仅纳入母亲接种Td3ap疫苗或未接种任何Tdap疫苗的病例和对照。
  • 共纳入108例病例和183例对照。
  • 使用条件logistic回归的频率学方法评估美国数据中Td3ap母亲免疫与婴儿百日咳的关联。
  • 采用贝叶斯动态借用非美国数据(历史非美国疫苗有效性数据权重90%,模糊先验权重10%)进行稳健性分析。

主要发现

  • 基于美国数据,孕晚期接种Td3ap疫苗预防2月龄以下婴儿百日咳的估计疫苗有效性为78.0%(95%CI:-38.0;96.5)。
  • 贝叶斯动态借用非美国数据(历史数据权重90%)估计的疫苗有效性为83.4%(95%可信区间:55.7;92.5)。
  • 敏感性分析产生了相似的疫苗有效性估计。

关键数值与推荐

  • 疫苗有效性计算公式为(1-比值比)×100%。

局限性

  • 品牌特异性亚组分析样本量小导致检验效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunisation during pregnancy with a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine can protect infants against pertussis between birth and paediatric vaccination. We aimed to estimate the vaccine effectiveness (VE) of third-trimester pregnancy immunisation with the three-component acellular pertussis (Td3ap) vaccine at preventing pertussis in infants <2 months in the United States (US), to support a label update. METHODS: We performed a post-hoc sub-analysis of a case-control study conducted in six US Emerging Infections Program Network states between 2011 and 2014. Our analysis included only cases and controls whose mothers were either vaccinated with Td3ap or did not receive any Tdap vaccine. The association between Td3ap maternal immunisation and pertussis in infants was assessed for US data using a frequentist method with conditional logistic regression. A robustified analysis was conducted using Bayesian dynamic borrowing of non-US data, considering a mixing-weighted prior of 90% for historical non-US VE data, and of 10% for a vague prior. VE was estimated as (1-odds ratio) × 100%. Sensitivity analyses accounting for the impact of each non-US study, different mixing weights and missing/ambiguous data were performed. RESULTS: We included 108 cases and 183 controls. Based on US data, the estimated VE of third-trimester maternal immunisation with Td3ap at preventing pertussis in infants <2 months was 78.0% (95% confidence interval: -38.0; 96.5). VE estimated by Bayesian dynamic borrowing of non-US data (with a 90% weight for historical data) was 83.4% (95% credible interval: 55.7; 92.5); sensitivity analyses produced similar VE estimates. CONCLUSIONS: Effectiveness of third-trimester pregnancy immunisation with Td3ap at preventing infant pertussis in the US is very likely to be ≥ 50% and is most likely ∼ 80%. Bayesian dynamic borrowing of non-US VE data allowed overcoming the limited power (due to small sample size) of a brand-specific sub-analysis by considering additional evidence.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cheuvart B, Callegaro A, Rosillon D, et al. Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing. Vaccine. 2023. PMID: 37635001. doi:10.1016/j.vaccine.2023.07.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。